Gelteq (GELS) Current Deferred Revenue (2024)
Gelteq (GELS) recorded quarterly Current Deferred Revenue of $77627.3 in Q4 2024, down 6.04% quarter-over-quarter from $82614.7 in Q2 2024.
Gelteq (GELS) Current Deferred Revenue (2024) Analysis & Trends
Gelteq's Current Deferred Revenue history runs 1 years deep, the most recent figure standing at $77627.3 for Q4 2024.
- In Q4 2024, Current Deferred Revenue changed N/A year-over-year to $77627.3; the TTM figure through Dec 2024 stood at $77627.3 (changed N/A YoY), while the FY2024 annual figure was $82614.7, changed N/A from the prior year.
- Current Deferred Revenue was $77627.3 for Q4 2024 at Gelteq, down from $82614.7 in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $82614.7 in Q2 2024 to a low of $77627.3 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn |
| 10 | Gelteq | 10.57 Mn | 10.34 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 77,627.26 |
| Jun 30, 2024 | 82,614.65 |